MET
8 drugsMesenchymal-Epithelial Transition Factor
Predictive biomarker for patient selection in 11 indications
Understanding MET
What it means: MET alterations include amplification, exon 14 skipping mutations, and overexpression. Drives cancer growth and metastasis.
Why it matters: MET inhibitors (capmatinib, tepotinib) show high response rates in MET exon 14 skipping mutations.
Testing: Tested via NGS for mutations, FISH for amplification, IHC for overexpression. Liquid biopsy can detect MET alterations.
8
Approved Drugs
11
Indications
7
Companies
MET is a precision-medicine biomarker linked to 8 FDA-approved targeted drugs from 7 companies, spanning 11 indications including Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Anaplastic Large Cell Lymphoma. Explore the targeted therapies, indications, testing methods, and companies developing MET drugs below.
Search MET Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting MET
MET Indications
Non-Small Cell Lung Cancer Medullary Thyroid Cancer Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumor Advanced renal cell carcinoma Hepatocellular carcinoma previously treated with sorafenib Locally advanced or metastatic differentiated thyroid cancer Well-differentiated pancreatic neuroendocrine tumors Well-differentiated extra-pancreatic neuroendocrine tumors Metastatic non-small cell lung cancer (NSCLC) with a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping Metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.